3OY1

Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacokinetic Properties

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 0.299 
  • R-Value Work: 0.258 
  • R-Value Observed: 0.259 

wwPDB Validation   3D Report Full Report



Literature

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.

Probst, G.D., Bowers, S., Sealy, J.M., Truong, A.P., Hom, R.K., Galemmo, R.A., Konradi, A.W., Sham, H.L., Quincy, D.A., Pan, H., Yao, N., Lin, M., Toth, G., Artis, D.R., Zmolek, W., Wong, K., Qin, A., Lorentzen, C., Nakamura, D.F., Quinn, K.P., Sauer, J.M., Powell, K., Ruslim, L., Wright, S., Chereau, D., Ren, Z., Anderson, J.P., Bard, F., Yednock, T.A., Griswold-Prenner, I.

(2011) Bioorg Med Chem Lett 21: 315-319

  • DOI: 10.1016/j.bmcl.2010.11.010
  • Primary Citation of Related Structures:  
    3OY1

  • PubMed Abstract: 

    • In this Letter, we describe the discovery of selective JNK2 and JNK3 inhibitors, such as 10, that routinely exhibit >10-fold selectivity over JNK1 and >1000-fold selectivity over related MAPKs, p38α and ERK2. Substitution of the naphthalene ring affords ...

    In this Letter, we describe the discovery of selective JNK2 and JNK3 inhibitors, such as 10, that routinely exhibit >10-fold selectivity over JNK1 and >1000-fold selectivity over related MAPKs, p38α and ERK2. Substitution of the naphthalene ring affords an isoform selective JNK3 inhibitor, 30, with approximately 10-fold selectivity over both JNK1 and JNK2. A naphthalene ring penetrates deep into the selectivity pocket accounting for the differentiation amongst the kinases. Interestingly, the gatekeeper Met146 sulfide interacts with the naphthalene ring in a sulfur-π stacking interaction. Compound 38 ameliorates neurotoxicity induced by amyloid-β in human cortical neurons. Lastly, we demonstrate how to install propitious in vitro CNS-like properties into these selective inhibitors.

    Organizational Affiliation: 

    Department of Medicinal Chemistry, Elan Pharmaceuticals, 180 Oyster Point Boulevard, South San Francisco, CA 94080, United States. gary.probst@elan.com



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 10 A362Homo sapiensMutation(s): 0 
Gene Names: MAPK10, JNK3, JNK3A, PRKM10, SAPK1B
EC: 2.7.11.24
Find proteins for P53779 (Homo sapiens)
Explore P53779 
Go to UniProtKB:  P53779
NIH Common Fund Data Resources
PHAROS:  P53779
GTEx:  ENSG00000109339
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
589
Query on 589
Download Ideal Coordinates CCD File 
A
5-[2-(cyclohexylamino)pyridin-4-yl]-4-naphthalen-2-yl-2-(tetrahydro-2H-pyran-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one
C28 H31 N5 O2
YZJYYYWPZRYBLV-UHFFFAOYSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
589IC50:  420   nM  BindingDB
589IC50:  16   nM  BindingDB
589IC50:  16   nM  Binding MOAD
589IC50 :  16   nM  PDBBind
589IC50:  97   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 0.299 
  • R-Value Work: 0.258 
  • R-Value Observed: 0.259 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 52.126α = 90
b = 71.328β = 90
c = 107.752γ = 90
Software Package:
Software NamePurpose
CrystalCleardata collection
AMoREphasing
REFMACrefinement
d*TREKdata reduction
d*TREKdata scaling

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2011-08-17
    Type: Initial release